2012Current clinical neurologyRequires access

Parkinson’s Disease: Levodopa-Induced Dyskinesia

Roongroj Bhidayasiri, Daniel Tarsy

Open publisher page 1 citations

Abstract

Although very effective, chronic levodopa therapy for Parkinson’s disease (PD) is frequently complicated by the subsequent development of motor complications, which take the form of fluctuations of bradykinesia, rigidity, and tremor- and levodopa-induced dyskinesia and dystonia. With each year of levodopa treatment, about 10% of patients develop motor complications. Young age of PD onset, disease duration and severity, and high doses of levodopa are recognized risk factors for the appearance of motor complications. These complications continue to be a source of disability for PD patients and are a major limiting factor in the therapeutic efficacy of levodopa. These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

About this research paper

What this paper is about

Although very effective, chronic levodopa therapy for Parkinson’s disease (PD) is frequently complicated by the subsequent development of motor complications, which take the form of fluctuations of bradykinesia, rigidity, and tremor- and levodopa-induced dyskinesia and dystonia. With each year of levodopa treatment, about 10% of patients develop motor complications. Young age of PD onset, disease duration and severity, and high doses of levodopa are recognized risk factors for the appearance of motor complications. These complications continue to be a source of disability for PD patients and are a major limiting factor in the therapeutic efficacy of levodopa. These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Although very effective, chronic levodopa therapy for Parkinson’s disease (PD) is frequently complicated by the subsequent development of motor complications, which take the form of fluctuations of bradykinesia, rigidity, and tremor- and levodopa-induced dyskinesia and dystonia. With each year of levodopa treatment, about 10% of patients develop motor complications. Young age of PD onset, disease duration and severity, and high doses of levodopa are recognized risk factors for the appearance of motor complications. These complications continue to be a source of disability for PD patients and are a major limiting factor in the therapeutic efficacy of levodopa. These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Key concepts: Levodopa, Dyskinesia, Medicine, Parkinson's disease, Dystonia, Disease, Limiting, Degenerative disease

Related papers

Back to paper searchBrowse research topicsOriginal source
Parkinson’s Disease: Levodopa-Induced Dyskinesia — Research Paper | ScholarLens